TABLE 3.
Clinical trials for ovarian cancer using nanoformulations
| Compound Name | Formulation | Active agent | Status for ovarian cancer | Trial No., Refs. |
|---|---|---|---|---|
| Doxil | PEGylated liposomal doxorubicin | Doxorubicin | FDA approved | NCT00945139, NCT00862355, NCT00248248 |
| - | Liposomal topotecan | Topotecan | Phase I | NCT00765973 |
| OSI-211 | Liposomal lurotecan | Lurotecan | Phase II | NCT00010179 |
| Abraxane, ABI-007 | Nanoparticle bound albumin paclitaxel | Paclitaxel | Phase II Approved for breast, small cell and pancreatic cancers |
NCT00466986, NCT00407563, 96–98, 187 |
| Xyotax | Paclitaxel poliglumex | Paclitaxel | Phase II | NCT00060359, NCT00017017, 99, 101 |
| Nanotax | Nanoparticle suspension | Paclitaxel | Phase I | NCT00666991 |
| NKTR-102 | Etirinotecan pegol | Topoisomerase I inhibitor | Phase II | NCT00806156103, 104 |
| CRLX101 | Cyclodextrin-PEG Camptothecin |
Camptothecin | Phase I | NCT00333502, NCT01652079, 105 |
| ProLindac (AP5346) | HPMA-oxaliplatin analogue | Oxaliplatin analogue | Phase II | 106, 107 |
| AP5280 | HPMA-carboplatinate analogue | Carboplatin analogue | Phase II | 107, 108, 188 |